主页 > 医药科学 >
【drug-news】PANC公司HIV药物检测未能尽如人意
Washington Business Journal - 9:41 AM EST
Wednesdayby Vandana SinhaStaff Reporter
Panacos Pharmaceuticals reported that its tablet to treat HIV did not work as well as hoped in preliminary tests, but the company plans to seek approval to test a higher-dose version.
The drug, bevirimat, was tested in a Phase IIb study on HIV-infected patients who failed previous traditional treatments.
Watertown, Mass.-based Panacos, which owns a research facility in Gaithersburg, says that during a two-week treatment cycle a 400-milligram version of the tablet performed similar to lower milligram versions in other trials.
Panacos says new formulations of the 400-milligram tablet may have resulted in the lower-than-expected response. It says the tablet did do well in terms of overall antiviral response and safety.
"While this first cohort did not produce the bevirimat levels we had hoped for, we were encouraged that some patients exhibited a very good antiviral response," says Graham Allaway, president and chief operating officer in a statement. "We believe the results support going to higher doses, potentially with alternative formulations, with the aim of generating greater responses."
The company says it plans to apply to the Food and Drug Administration to hike up the dose in the Phase IIb study "as soon as possible."
Panacos (NASDAQ: PANC) announced the test results after the closing bell. The share price, which closed Tuesday at $5.69 after a nearly 6 percent drop, plummeted even further in after-hours trading. It fell 35 percent or $1.99, to $3.70, which was 50 cents beneath the 52-week low.
http://washington.bizjournals.com/washington/stories/2006/12/18/daily33.html?jst=b_ln_hl 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Test of HIV drug disappointing, firm says
PANC公司HIV药物检测未能尽如人意
Washington Business Journal - 9:41 AM EST
Wednesdayby Vandana SinhaStaff Reporter
Panacos Pharmaceuticals reported that its tablet to treat HIV did not work as well as hoped in preliminary tests, but the company plans to seek approval to test a higher-dose version.
Panacos药物公司宣布该公司的抗HIV药物并没有像原来一期实验时那样起作用，但该公司计划申请更大剂量的使用该药物以测试该药物的效果。
The drug, bevirimat, was tested in a Phase IIb study on HIV-infected patients who failed previous traditional treatments.
这种新的抗癌药bevirimat在第二阶段临床试验中，是在已经尝试过传统疗法的HIV感染患者中测试药效。
Watertown, Mass.-based Panacos, which owns a research facility in Gaithersburg, says that during a two-week treatment cycle a 400-milligram version of the tablet performed similar to lower milligram versions in other trials.
位于水镇的Panacos公司在盖斯堡有着一个研究中心，宣称两周400mg的疗法跟低剂量的疗法效果相近。
Panacos says new formulations of the 400-milligram tablet may have resulted in the lower-than-expected response. It says the tablet did do well in terms of overall antiviral response and safety.
Panacos公司宣称新的400mg配方的药物可能导致了低于预期的反应，但是该药物确实是有着良好的抗病毒效果和安全性。
"While this first cohort did not produce the bevirimat levels we had hoped for, we were encouraged that some patients exhibited a very good antiviral response," says Graham Allaway, president and chief operating officer in a statement. "We believe the results support going to higher doses, potentially with alternative formulations, with the aim of generating greater responses."
Panacos的总裁格拉汉姆-沃厄伟Graham Allaway说道“虽然第一批患者体内的Bevirimat的水平未达到我们的预期，但某些患者非常好的抗病毒反应让我们感到鼓舞”他继续说道“我们相信这样的结果意味着我们要使用更大的脊梁，可能使用不同的配方，因此可能产生更好的抗病毒反应。”
The company says it plans to apply to the Food and Drug Administration to hike up the dose in the Phase IIb study "as soon as possible."
Panacos公司宣称将尽快地向FDA申请以期能在临床IIb实验中使用更大的剂量。
Panacos (NASDAQ: PANC) announced the test results after the closing bell. The share price, which closed Tuesday at $5.69 after a nearly 6 percent drop, plummeted even further in after-hours trading. It fell 35 percent or $1.99, to $3.70, which was 50 cents beneath the 52-week low.
Panacos (纳斯达克: PANC)宣布药物的实验结果在停盘之后，股票的价格星期二是5.69美元下降了将近6%，在开盘后的几个钟头内继续下降，每股下降了35%也就是1.99美元，现在的股价3.70美元，比52周来的最低价还低了50美分。 PANC公司HIV药物检测未能尽如人意
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-04-23 05:14
医学,生命科学网